# Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

> **NCT00569127** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 427 (actual)

## Conditions studied

- Colorectal Neuroendocrine Tumor G1
- Gastric Neuroendocrine Tumor G1
- Neuroendocrine Neoplasm
- Neuroendocrine Tumor
- Neuroendocrine Tumor G2

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Octreotide Acetate
- **BIOLOGICAL:** Recombinant Interferon Alfa-2b

## Key facts

- **NCT ID:** NCT00569127
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2007-12-01
- **Primary completion:** 2015-01-01
- **Final completion:** 2027-01-31
- **Target enrollment:** 427 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00569127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00569127, "Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00569127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*